Jennewein accuses Nestlé of infant formula patent infringement

By Will Chu

- Last updated on GMT

©iStock/
©iStock/

Related tags: Jennewein, Nestlé, HMO

Jennewein Biotechnologie has filed a patent infringement suit against Nestlé concerning the unauthorised use of a human milk oligosaccharide (HMO) purification method for infant formula.

Jennewein, which filed the suit with the Mannheim regional courts last week, claims that Nestlé’s infant formula brand Beba Supreme contains the HMOs 2'-Fucosyllactose (2'-FL) and Lacto-N-Neotetraose (LNnT) purified by the patent-protected process.

In addition, the German firm claims to have evidence that Nestle infant formulas marketed under different trade names also include the two HMOs produced by the purification method.

“As Nestlé offers its infant food containing human milk oligosaccharides not just in Germany, Jennewein currently investigates measures against the assumed infringement of its corresponding foreign patents by the manufacturing of products such as Illuma, SMA, NAN and Gerber Good Start,”​ says Jennewein.

Purity of at least 80 %’

The firm’s patent attorney Dr Andreas Hübel explains that the exact process protected by the patents (EP 2896628​ and EP 3131912​) is a method for the purification of neutral HMOs such as 2’-FL and LNnT from a fermentation broth.

“This process involves removal of biomass from the fermentation broth, subjecting the cell-free fermentation broth to ion exchange treatment, followed by electrodialysis and/or nanofiltration,”​ he says.

“Pursuant to one of the patents, the process further involves spray-drying the HMO. The process leads to a preparation of a neutral HMO from the fermentation broth having a purity of at least 80 %.”

“It is our understanding that Nestle uses said two neutral HMOs for the production of their HMO-containing infant formula, wherein said HMOs have been produced by a process that involves the purification scheme that is proprietary to Jennewein Biotechnologie,”​ adds Dr Hübel.

Jennewein now request that Nestlé Nutrition and its holding company Nestlé Deutschland AG cease the use of the HMOs that infringe Jennewein’s intellectual property rights.

Responding to the allegations, a spokesperson for Nestlé said that the company had not received any official notification on the matter and were therefore unable to comment.

Related news

Show more

Related products

show more

Turmacin®: Clean Label & Clinically Tested Turmeric

Turmacin®: Clean Label & Clinically Tested Turmeric

Natural Remedies Private Limited | 01-Sep-2021 | Product Presentation

Turmacin® is a clean label project-certified, clinically tested, and clinically safe turmeric extract. Turmacin® is rich in Turmerosaccharides® and doesn't...

Quatrefolic®: The Active folate vs Folic Acid

Quatrefolic®: The Active folate vs Folic Acid

Gnosis by Lesaffre USA | 31-Aug-2021 | Infographic

Folate deficiency concerns everyone at every step of their life. The supplementation of vitamin B9 is often be misunderstood, especially regarding the...

Actilight® and infant nutrition: new perspectives

Actilight® and infant nutrition: new perspectives

Tereos | 31-Aug-2021 | Technical / White Paper

Addition of prebiotic ingredients to formulas started around 30 years ago and is widely recognized by experts. Actilight® scFOS is safe for use in infant...

Business case: private label iron supplements

Business case: private label iron supplements

PharmaLinea Ltd. | 18-May-2021 | Case Study

A line of clinically supported private label iron supplements by PharmaLinea is selling nearly 500.000 units/year in a market of under 20 million people.

Related suppliers

Follow us

Products

View more

Webinars